By winter’s end, the Neutron’s first flight shall etch its name in the sky. A ceremonial unveiling, yes-but also the threshold of commerce, where contracts bloom like frostflowers. Yet should one wager on this flight before the wings are tested?
From the very outset of his investing career, Buffett’s strategy has been centered around ownership of “outstanding businesses,” with little regard for the passing market whims. Yet, even the most astute investor must recognize when a once-prized asset has become overinflated, or when, as is sometimes the case, the portfolio grows so large that even the most successful of investments needs pruning. It is this fine art of pruning-often with surgical precision-that has led to the recent divestments in Berkshire Hathaway’s portfolio. In fact, for the past 11 quarters, the company has sold more equities than it has purchased. Indeed, when one considers the story of BYD, one cannot help but wonder if the decision to sell was yet another manifestation of the age-old adage: “It’s better to be lucky than good.”
Currently, two noteworthy contenders in the electric vehicle (EV) arena are Rivian Automotive (RIVN) and Lucid Group (LCID). While both companies exhibit traits reminiscent of Tesla, evidence implies that one may emerge as a more favorable investment at this juncture. A thorough examination of each is warranted.
Pharma giants don’t crumble overnight. Their decay is a slow rot, visible in the cracks of patent walls and the shifting sands of public trust. Let us dissect this carcass to see if its bones hold marrow enough for resurrection.
Chevron, bless its oil-slicked heart, has a business model that’s as versatile as it is resilient-like your favorite sweater on a bad hair day. They’re digging deep into energy production, transportation, and refining, romancing every angle of the energy dance floor. When commodities are playing hot potato-soaring high or crashing low-Chevron’s diversified portfolio acts like a comfortable couch to fall back on.
One might be tempted to scoff at the notion that a company-whose glory days of mainframes and punch cards are but distant echoes-could emerge as a titan in the AI revolution. And yet, dear reader, there lies the crux of it: IBM’s unique charm is in its ability to cater not to the whims of the common folk, but to the insatiable demands of the Fortune 500. A new-age charlatan disguised as a corporate sage, if you will.
Yet let us peer deeper, into the trembling heart of this matter. The company’s tirzepatide-marketed as Mounjaro and Zepbound-has already proven a siren song to millions, its weekly subcutaneous injections a ritual of modern salvation. But the needle, though precise, is a relic. The true battleground lies in the pill-a form so ancient, so deceptively simple, yet capable of igniting the same primal hunger for ease, for comfort, for the illusion of control over flesh and fate.
Resilience isn’t a headline. It’s a ledger entry. Recession, war, market crashes-they’re all the same to these relics. Their secret? Cash flows smoother than a silk suit and dividends that rise like the tide, whether you’re watching or not.
The sellers have made merry recently, but signs suggest that their nocturnal festivities may be drawing to a timely conclusion. Support rests humbly at $107,000 to $107,500, whilst resistance firmly stands its ground between $114,000 and $117,000. Break through $111,000, and the bulls may find cause to briefly renew their vigour, or so the conjecture goes.
Costco, the venerated titan of retail, extends its influence through 914 warehouses scattered across the globe and a burgeoning e-commerce presence in major metropolises. The harmonious simplicity of its limited-SKU model intertwined with its prowess in private label branding fortifies its promise of low prices-a symphony that echoes through the steady pulse of foot traffic and dependable fee income. With the unveiling of the latest quarterly figures, the question that looms large over the investors’ minds, rich in both intrigue and trepidation, emerges: Do the heights of this stock’s current price retain their rationale?